I am the CEO and founder of BLR Bio, an emerging biotech with a platform of therapeutic peptides and a companion diagnostic focused on the treatment of cancer and fibrotic disease. Our first-in-class technology is based on a discovery in an academic laboratory I headed at Rosalind Franklin University, while also Director of R&D at Baxter Healthcare's Renal Division. We discovered that the matricellular signaling CCN3 is a natural regulator of the pro-fibrotic and pro-cancer CCN2 working down multiple pathways. This led us to discover, create, and test unique synthetic peptides which we have now shown to be specific, stable, safe, and effective in animal in variety of human disease models. These include, pancreatic cancer, diabetic kidney disease, endstage renal disease, NASH, scleroderma, and skin scarring. We are now, for the first time, seeking investor/partners to move our lead novel therapies to the clinic.